SCHEMBL26817834

SCHEMBL26817834

C=C(Cn1c(C)nc2ccccc21)N=[N+]=[N-]

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.50
▸ TSHR P16473 3/20 0.50
▸ HTT P42858 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ TNF P01375 1/20 0.48
▸ ALPL P05186 2/20 0.46
▸ ALPG P10696 2/20 0.46
▸ GSK3B P49841 2/20 0.46
▸ ALPP P05187 1/20 0.46
▸ PLAA Q9Y263 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ GALR3 O60755 3/20 0.46
▸ NR2F2 P24468 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26817872 0.85 LMNA (0.50) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL26817860 0.76 ATM (0.47) LMNATSHRSMN1; SMN2HSD17B10MEN1
SCHEMBL26817828 0.72 TDP1 (0.50) LMNAHTTSMN1; SMN2TNFALPL
SCHEMBL3587930 0.72 KDM4E (0.69) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL31498004 0.71 TNF (0.64) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL4191641 0.71 TNF (0.64) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL5252741 0.71 LMNA (0.60) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL6446137 0.70 LMNA (0.69) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL1104819 0.69 TNF (0.66) LMNATSHRHTTSMN1; SMN2ALDH1A1
SCHEMBL12497263 0.69 LMNA (0.69) LMNATSHRHTTSMN1; SMN2ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382946-A1 POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING Changzhou University (CN) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382946-A1 POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING PTMS, CBS, CHAMP1 LMNA 4376/4885TSHR 1863/4885HTT 2090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback